MARKET

INNT

INNT

INNOVATE BIOPHARMACEUTICALS INC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.060
+0.020
+1.92%
Closed 16:00 10/18 EDT
OPEN
1.100
PREV CLOSE
1.040
HIGH
1.100
LOW
1.040
VOLUME
180.04K
TURNOVER
--
52 WEEK HIGH
5.39
52 WEEK LOW
0.7280
MARKET CAP
2.72M
P/E (TTM)
-2.4102
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of INNT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

INNT News

  • Triangle drugmaker plans merger with Israeli pharma -- what it means for Raleigh
  • American City Business Journals.10/07 19:38
  • SPWR, FRO among premarket gainers
  • Seeking Alpha - Article.10/07 13:15
  • 16 Healthcare Stocks Moving In Monday's Pre-Market Session
  • Benzinga.10/07 12:09
  • Innovate Biopharmaceuticals to Merge with RDD Pharma Creating New Gastroenterology Company Focused on Specialty, Rare and Orphan Diseases
  • ACCESSWIRE.10/07 11:00

More

Industry

Biotechnology & Medical Research
-1.17%
Pharmaceuticals & Medical Research
-0.94%

Hot Stocks

Name
Price
%Change

About INNT

Innovate Biopharmaceuticals, Inc., formerly Monster Digital, Inc., is a clinical stage biotechnology company. The Company is focused on developing novel autoimmune and inflammation therapeutic drugs. Its lead drug candidate, larazotide acetate (INN-202) is a tight junction regulator. Its other products include INN-108 and INN-329 (Secretin). The Company’s INN-108 is a novel small molecule comprised of two active parts with anti- inflammatory and immunodulatory properties coupled through an azo bond. The Company is developing INN-108 as a therapeutic for Ulcerative Colitis (UC). Its Secretin stimulated magnetic resonance cholangiopancreatography (MRCP) is a ionizing, radiation-free assessment of the pancreaticobiliary system. The Company has completed a phase II b clinical trial for celiac disease for INN-202. It is developing INN-108 in a phase II trial for inflammatory bowel disorders, mild to moderate UC and a Gastrointestinal (GI) orphan disease.
More

Webull offers Innovate Biopharmaceuticals Inc (INNT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.